secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001104659-23-080013
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance prices $150M public offering of 20M shares at $7.50; underwriter option for 3M more
--------------------------------------------------------------------------------

- Priced 20M shares at $7.50/share for gross proceeds of $150M; net proceeds ~$140.2M.
- Underwriters granted 30-day option for up to 3M additional shares; total offering up to 23M shares.
- Proceeds to fund lifileucel commercial launch prep, manufacturing facility, and clinical programs.
- Offering led by Goldman Sachs & Co. LLC and Jefferies LLC; expected to close July 13, 2023.
- Executive officers and directors entered 90-day lock-up agreements on stock sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923080013/0001104659-23-080013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923080013/tm2320915d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer